Cargando…
LAG3 and PD1 Regulate CD8+ T Cell in Diffuse Large B-cell Lymphoma Patients
BACKGROUND: Diffuse large B-cell lymphoma (DLBCL) is a clinically and genetically heterogeneous lymphoid malignancy. The unsatisfactory outcome for refractory patients has prompted efforts to explore new therapeutic approaches for DLBCL. However, the mechanisms involved in treatment associated with...
Autores principales: | Liu, Ying, Guo, Xinhong, Zhan, Lingbo, Wang, Lei, Wang, Xinyou, Jiang, Ming |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8378962/ https://www.ncbi.nlm.nih.gov/pubmed/34422089 http://dx.doi.org/10.1155/2021/4468140 |
Ejemplares similares
-
Retracted: LAG3 and PD1 Regulate CD8+ T Cell in Diffuse Large B-cell Lymphoma Patients
por: Methods in Medicine, Computational and Mathematical
Publicado: (2023) -
The immune checkpoint molecules PD-1, PD-L1, TIM-3 and LAG-3 in diffuse large B-cell lymphoma
por: Chen, Benjamin J., et al.
Publicado: (2019) -
Blockade of PD-1 and LAG-3 expression on CD8+ T cells promotes the tumoricidal effects of CD8+ T cells
por: Ma, Jiajia, et al.
Publicado: (2023) -
Prognostic Value of PD-L1, PD-1 and CD8A in Canine Diffuse Large B-Cell Lymphoma Detected by RNAscope
por: Aresu, Luca, et al.
Publicado: (2021) -
Defining Diffuse Large B-Cell Lymphoma Immunotypes by CD8+ T Cells and Natural Killer Cells
por: Qi, Jing, et al.
Publicado: (2022)